Thank you for signing up!

NORDIC I 16th of June 2021 | 15:00 - 17:00 PM

You will receive an email containing the link to the meeting prior to the meeting date from Line.Arctander@sanofi.com, remember to save the date in your calendar!

Management of Relapsed and Refractory Multiple Myeloma with novel monoclonal antibody-based regimens: from evidence-based considerations to clinical practice with ▼SARCLISA®

The evolving landscape of multiple myeloma 2021: updates on the management of RRMM with novel monoclonal antibody regimens

In this meeting you will learn more about the evolving treatment paradigm for relapsed remitting multiple myeloma in 2021, challenges in treating refractory patients and the latest update on ▼Sarclisa®, a new EMA-approved treatment option for RRMM patients.

▼SARCLISA® (isatuximab) is a monoclonal antibody that targets a specific epitope on the CD38 receptor of a plasma cell.

Learn more about the medical data from the IKEMA trial for ▼SARCLISA® and listen as MD PhD Fredrik Schjesvold guides discussions with Prof. Philippe Moreau and Prof. Torben Plesner.

AGENDA

15:00-15:15

Welcome by Sanofi Genzyme and intro
MD PhD Fredrik Schjesvold

15:15-16:00

AntiCD38 monoclonal antibody therapy in combinations with carfilzomib and dexamethasone
Prof. Philippe Moreau

16:00-16:05

Coffee break

16:05-16:30

CD38 antibodies for treatment of myeloma: Modes of action and implications for treatment failure
Prof. Torben Plesner

16:30-17:00

Q&A and discussion: how to optimize the treatment sequence with available treatments in MM patients?
Moderated by MD PhD Fredrik Schjesvold

Professor Philippe Moreau
Professor of Hematology. Nantes University Hospital, France

Prof. Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France. He specializes in clinical hematology, with a particular focus on multiple myeloma and its treatment with high-dose therapy and novel agents. As leading researcher in multiple myeloma, Prof. Moreau is head of the unit for early phase 1 and phase 2 trials in clinical hematology at the University Hospital of Nantes. Prof. Moreau is currently a member of the administration council f the Intergroupe Francophone du Myélome (IFM), and he was chairman of the IFM from 2006 through 2009. Prof. Moreau is widely published, with more than 240 per-reviewed articles and reviews that have appeared in high impact factor journals including New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, and Blood.

Professor Torben Plesner
Professor of Hematology. University of Southern Denmark, Odense & Vejle Hospital, Denmark

Prof. Torben Plesner, MD, is a world-renowned myeloma expert and currently practices hematology at Vejle Hospital in Denmark and is a Professor at the University of Southern Denmark. Prof. Plesner was involved in the earliest work on daratumumab. He has been leading clinical trials and have several peer-reviewed articles published in impact journals.

MD, PhD Fredrik Schjesvold
Founder and leader of Oslo Myeloma Center at Oslo University Hospital, Norway

Fredrik Schjesvold, MD, PhD, is the founder and leader of Oslo Myeloma Center at Oslo University Hospital. He earned his medical degree from the University of Oslo in 2001. He has previously headed the units of hematology at Diakonhjemmet hospital and Bærum hospital in Norway.

Dr. Schjesvold is an international expert on Multiple Myeloma, with one of Europe’s largest centers for clinical research in this disease. This includes being the national coordinator of 30 clinical myeloma trials, and in addition being the principal investigator of 3 large myeloma studies. He is also an expert on light chain amyloidosis.

MAT-NO-2100432 -v.1.0-Mai 2021

▼Sarclisa® Felleskatalogen